5 Key Takeaways
-
1
EYP-1901 demonstrated early efficacy in controlling nonproliferative diabetic retinopathy (NPDR) despite missing its 12-month primary endpoint in the PAVIA trial.
-
2
Patients treated with EYP-1901 maintained stable or improved disease status through 12 months after a single injection, according to trial results.
-
3
The bioerodible implant, containing vorolanib, showed positive results at 6 months but the treatment effect diminished after approximately 9 months.
-
4
EYP-1901 was well tolerated with no new safety concerns, reinforcing its favorable safety profile observed in previous trials for other conditions.
-
5
EyePoint Pharmaceuticals plans a phase 3 trial for NPDR, leveraging insights from the PAVIA trial regarding the implant's durability and treatment effects.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.